Who are disodium EDTA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): EDTA root conditioning, Citrate 4%, Edetate Calcium Disodium, Dosage of Calcium edetate de sodium, Penicillamine (D1-W12).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/disodium-edta.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

disodium EDTA — Competitive Intelligence Brief

disodium EDTA (disodium EDTA) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chelating agent. Area: Toxicology / Nephrology.

marketed Chelating agent Divalent metal cations (Pb²⁺, Cd²⁺, Ca²⁺, Zn²⁺) Toxicology / Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

disodium EDTA (disodium EDTA) — Mt. Sinai Medical Center, Miami. Disodium EDTA is a chelating agent that binds and removes heavy metals and excess divalent cations from the bloodstream.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
disodium EDTA TARGET	disodium EDTA	Mt. Sinai Medical Center, Miami	marketed	Chelating agent	Divalent metal cations (Pb²⁺, Cd²⁺, Ca²⁺, Zn²⁺)
EDTA root conditioning	EDTA root conditioning	Ain Shams University	marketed	Chelating agent	Calcium ions and divalent cations in mineralized tooth structure
Citrate 4%	Citrate 4%	Centre Hospitalier Universitaire Dijon	marketed	Anticoagulant (chelating agent)	Ionized calcium (Ca2+)
Edetate Calcium Disodium	Edetate Calcium Disodium	M.D. Anderson Cancer Center	marketed	Chelating agent	Heavy metal ions (lead, cadmium, zinc, and other divalent/trivalent cations)
Dosage of Calcium edetate de sodium	Dosage of Calcium edetate de sodium	University Hospital, Limoges	phase 3	Heavy metal chelating agent	Lead and other heavy metal ions (Pb²⁺, Cd²⁺, Zn²⁺)
Penicillamine (D1-W12)	Penicillamine (D1-W12)	Orphalan	phase 3	Chelating agent	Heavy metal ions (copper, mercury, lead); thiol-reactive compounds

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chelating agent class)

Ain Shams University · 1 drug in this class
Alexion Pharmaceuticals, Inc. · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class
Mt. Sinai Medical Center, Miami · 1 drug in this class
Orphalan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). disodium EDTA — Competitive Intelligence Brief. https://druglandscape.com/ci/disodium-edta. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab